Automation Workflow for Antibody and Biologic Drug Discovery

This workflow automates the high-cost bottleneck of empirical antibody screening. It replaces manual sequence library management and low-throughput lab assays with a coordinated, AI-driven pipeline that models protein-protein interactions, predicts immunogenicity, and assesses stability and expression levels in silico. The operational upside comes from expanding the searchable sequence space by orders of magnitude, shrinking lead identification from months to weeks, and reducing wet-lab resource consumption by prioritizing only the most promising candidates for expression and binding validation.

Implementation integrates specialized agents with enterprise systems. A LangGraph-based orchestrator sequences tasks: a generative agent proposes humanized variants, a physics-based agent scores binding, and a profiling agent checks aggregation risk. Results populate a unified candidate registry, with scores fused by a custom MPO engine. Governance is enforced through electronic lab notebook (ELN) integrations for traceability and mandatory human review gates before synthesis orders are sent to CROs or internal platforms. The architecture requires robust model monitoring to track prediction drift against eventual lab results.

This workflow automates the high-cost, empirical bottleneck of biologic lead identification. It replaces manual sequence screening and lab-intensive affinity maturation with a coordinated multi-agent system. Specialized AI agents model protein-protein interactions, predict immunogenicity, and assess stability and expression levels in silico. The orchestration ranks thousands of candidate variants against a multi-parameter target profile, prioritizing only the most promising for experimental testing. This expands the searchable sequence space, improves lead candidate quality, and directly reduces wet-lab screening costs and project timelines.

Implementation integrates with existing R&D systems: the orchestrator, built on LangGraph or a custom state machine, triggers agents that call specialized bio-AI models (AlphaFold, ESM). Results are aggregated into a unified scoring engine applying project-specific MPO rules. All decisions, data, and model versions are logged to an immutable audit trail for governance. Critical human review gates are embedded before synthesis requests are sent to the ELN. The final architecture connects cloud HPC, internal bioinformatics pipelines, and the compound management system, creating a closed-loop Design-Make-Test-Analyze cycle for biologics.

A custom biologic discovery workflow automates the high-volume, iterative process of antibody sequence optimization, developability profiling, and candidate prioritization. The operational upside comes from compressing months of manual bioinformatics analysis and empirical testing into a continuous, agent-driven design loop. Savings are realized through reduced computational waste, higher-quality leads entering expensive wet-lab validation, and a 70-80% reduction in sequence screening cycle times. The architecture integrates specialized agents for PPI modeling, immunogenicity prediction, and stability scoring, orchestrated via LangGraph and connected to ELN and LIMS systems.

Implementation begins with a foundation phase integrating prediction APIs (e.g., AlphaFold, AbLang) and building a LangGraph orchestrator to manage state. The pilot focuses on a single, high-value workflow like affinity maturation, delivering a working system for a specific project team within 14-18 weeks. This de-risks adoption by proving ROI on a contained scope. The final scale phase adds integrations to Benchling or Dotmatics ELNs, implements full MPO scoring, and deploys monitoring for model drift. Each phase includes defined approval gates, exception routing for low-confidence predictions, and validation checkpoints against historical experimental data.

Effective governance starts with a clear decision hierarchy. The workflow must embed validation checkpoints where AI-generated antibody sequences or developability profiles are scored against predefined criteria—potency, immunogenicity risk, expression yield. These scores trigger automated routing: high-confidence candidates proceed to synthesis planning; borderline cases queue for human review by a computational biologist; failures are logged with rationale for model feedback. This structured exception handling prevents the propagation of poor candidates, protecting downstream lab resources and maintaining pipeline integrity.

Phased rollout mitigates operational risk. Phase 1 targets a single, well-characterized target antigen to validate the core orchestration between generative models, affinity predictors, and the ELN. Success metrics are precision—percentage of AI-proposed sequences that express and bind—not just throughput. Subsequent phases expand target scope, integrate more complex developability agents, and finally connect to robotic synthesis platforms. Each phase requires updated SOPs, user training, and recalibration of automated scoring thresholds based on newly generated experimental data, ensuring the system evolves with scientific learning.

This workflow directly attacks the operational bottleneck of stale predictive models in biologic discovery. As new wet-lab data on antibody sequences, binding affinities, and developability profiles is generated, specialized agents automatically validate model performance, detect prediction drift, and trigger retraining pipelines. The architecture orchestrates data ingestion from ELNs like Benchling, manages versioned model training on cloud HPC, and executes validation against hold-out sets. This creates a self-improving discovery loop where each candidate tested makes subsequent AI-driven predictions more accurate, reducing costly synthesis of poor candidates and accelerating the path to high-quality leads.

Implementation requires integrating with the compound registry and assay data warehouse, using frameworks like MLflow for model lifecycle management. Governance is critical: each new model version undergoes automated validation against predefined accuracy thresholds and requires a documented approval gate before deployment to the production design environment. This ensures regulatory traceability and maintains scientist trust in the AI recommendations. The result is a measurable reduction in the number of design-make-test-analyze cycles needed to converge on a developable biologic, directly improving R&D throughput and resource efficiency.